Prognostic association of routinely measured biomarkers in patients admitted to critical care: a systematic review. by Wan, YI et al.
 
 1 
Prognostic association of routinely measured biomarkers in patients 
admitted to critical care: a systematic review 
 
Yize I. Wan*a, b, Adam Braynea, b, c, Ryan W. Haines a, b, Zudin A. Puthucheary a, b, John R. 
Prowle a, b 
 
aAdult Critical Care Unit, The Royal London Hospital, Barts Health NHS Trust, London, UK 
bWilliam Harvey Research Institute, Queen Mary University of London, London, UK 
cNorthern Devon Healthcare NHS Trust, Barnstaple, Devon, UK 
 
*Corresponding author: 
Yize I. Wan, PhD 
Critical Care Research Office, 
The Royal London Hospital, 
London E1 1BB, 
United Kingdom 
Email: yize.wan@qmul.ac.uk 
Tel: +44 20 3594 0351 
 
Author’s Contributions: All authors reviewed and approved the final manuscript. YW and JP were 
responsible for the study concept and YW, RH, and JP for study design. Data extraction and analysis 
was undertaken by YW, AB, and RH. YW, RH, ZP, and JP wrote the manuscript. 
 




Prognostic association of routinely measured biomarkers in patients 
admitted to critical care: a systematic review 
 
Abstract 
Purpose: To examine reported prognostic associations of routine blood measurements in the 
intensive care unit. 
Materials and Methods: We searched PubMed, EMBASE through 28th May 2020 to identify 
all studies in adult critical care investigating associations between parameters measured 
routinely in whole blood, plasma or serum, and length of stay or mortality. Registration: 
PROSPERO; CRD42019122058. 
Results: A total of 128 studies, reporting 28 different putative prognostic biomarkers, met 
eligibility criteria. Those most frequently examined were red cell distribution width, 
neutrophil-to-lymphocyte ratio, C-reactive protein, and platelet count. A higher red cell 
distribution width, a lower platelet count, and a higher neutrophil-to-lymphocyte ratio were 
consistently associated with both increased mortality and length of stay. A lower level of 
albumin was consistently associated with greater mortality. C-reactive protein was 
inconsistent. Most studies (n=110) used regression modelling with wide variation in variable 
selection and covariate-adjustment; none externally validated the proposed predictive models. 
Conclusions: Simple regression models have so far proved inadequate for the complexity of 
data available from routine blood sampling in critical care. Adoption of a direct causal 
framework may help better assess mechanistic processes, aid design of future studies, and 
guide clinical decision making using routine data. 
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Panels of laboratory blood tests are routinely used for diagnosis and assessment of hospitalized 
patients (Badrick, 2013). In patients admitted to critical care, blood samples are frequently 
taken throughout the course of admission generating a large quantity of repeated measures data 
in every patient, only a little of which is directly utilized in clinical decision making (Ezzie et 
al., 2007). Large numbers of observational studies have investigated the association of routine 
laboratory test results to clinical outcomes within different subgroups of critically ill patients, 
including sepsis, acute kidney injury, and acute respiratory distress syndrome (Gerlach, 2018, 
Heilmann et al., 2019, Kelly et al., 2018, Opal and Wittebole, 2020, Vincent and Teixeira, 
2014, Koyner et al., 2019, Srisawat and Kellum, 2020, Ware et al., 2010). Furthermore, there 
has been a growing number of studies examining less frequently used indices in routine blood 
panels, or measures derived from combinations of routinely measured blood tests, including 
red cell distribution width and neutrophil-to-lymphocyte ratio which have been proposed as 
novel surrogate measures of pathophysiological pathways (Gluck et al., 2018, Hwang et al., 
2017, Güell et al., 2019, Bazick et al., 2011, Kim et al., 2013, Purtle et al., 2014). 
 
There is a long history of including haematological and biochemical parameters in models to 
estimate expected mortality and morbidity in critically ill patients (Vincent and Moreno, 2010, 
Breslow and Badawi, 2012a, Breslow and Badawi, 2012b). As mortality from critical illness 
continues to reduce, identification of high risk subgroups may be important to enable continued 
improvement in outcomes (Sjoding and Cooke, 2015). Furthermore, it is becoming accepted 
that simple survival does not constitute intensive care unit (ICU) success. An increasingly 
recognized syndrome of persistent critical illness is associated with significant ongoing 
morbidity, and poor post-ICU outcomes (Hermans et al., 2019, Jeffcote et al., 2019). However 
these phenotypes are poorly understood (Viglianti et al., 2019). Consequently, while there is 
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considerable interest in understanding biological signatures of critical illness phenotypes from 
routine blood investigations, interpretation and clinical application of these potential 
biomarkers remains ambiguous.  
 
Newer approaches using routinely collected data have used machine learning techniques for 
prediction of ICU morbidity and mortality with the aim of improving prognostic models and 
classifying sub-populations (Shillan et al., 2019). Studies have most commonly used 
supervized methods such as support vector machines, random forests, and neural networks. 
However, such hypotheses driven approaches may tend to reinforce pre-existing concepts 
rather than identifying novel groups. Furthermore, the majority of published studies have 
analysed data on relatively small patient populations, have no external validation, and lack 
complete reporting of predictive accuracy. There is currently limited statistical literature on 
how to evaluate the performance of these methods in clinical practice, particularly when more 
than one biomarker is involved or when outcome variables are classified using more than two 
categories. In these cases, traditional measures such as receiver operating characteristic (ROC) 
curves and the area under the ROC curve (AUC) are not applicable (Li et al., 2019). Thus, 
despite an apparent wealth of information, it is difficult to clearly determine true clinical 
associations and clinical implications of these models (Ware, 2017, Tyler et al., 2018). In this 
systematic review, we aimed to examine and collate reported associations between routine 
blood test results carried out in critical care and outcomes using ICU length of stay and 
mortality up to 90 days to identify useful candidates for future large-scale outcomes modelling 




Materials and methods 
This systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines (Moher et al., 2009). 
The study protocol was registered with the International Prospective Register of Systematic 
Reviews (PROSPERO; CRD42019122058). 
 
Study selection 
A study was eligible if it aimed to test the association between one or more routinely measured 
biomarker(s) and length of stay, and/or mortality. These outcomes were defined as 1) ICU or 
hospital length of stay, 2) mortality on the ICU or in hospital or within 90 days of ICU 
admission. Candidate biomarkers were any indices available from blood tests measured as part 
of a routine daily panel in international ICUs. Studies were restricted to those carried out in 
adults. Prospective and retrospective studies were included. Case reports and case series, as 
well as non-research publications such as literature reviews, editorials and correspondences 
were excluded. Only full text articles in English were included. 
 
Search strategy 
Searches were carried out using two separate databases MEDLINE (PubMed) and Excerpta 
Medica dataBASE (EMBASE) from inception through 28th May 2020. Search strategies are 
detailed in the online supplement, briefly these involved combinations of blood test name or 
terms for abnormalities in the measured parameter, terms indicative of critical illness and terms 
indicative of outcomes of relevance. Reference lists from prior systematic reviews were 





Data extraction was performed independently by three independent investigators (YW, AB, 
RH) and in duplicate using predefined data abstraction forms. A random check of 10% of cases 
were performed to ensure accuracy and any disagreements were resolved by a fourth 
investigator (JP). Abstracted data included study characteristics, demographic data, biomarker 
data and outcome data.  
 
Quality of evidence and risk of bias 
Quality of evidence and individual study risk of bias within studies was assessed using the 
Newcastle-Ottawa Scale (NOS) criteria (Wells et al., 2013). Scores were given based on 
selection of study groups (four points), comparability of groups (two points), and ascertainment 
of exposure and outcomes (three points). Statistical methods and models were assessed 
including statistical model type, method for variable selection for adjustment, and model 
performance metrics. In addition, we recorded studies that used an a priori statistical analysis 
plan and those that adhered to the appropriate STROBE reporting guidelines. We assessed 
citations and geographical location of studies. Study citations were reviewed using Pubmed, 
Crossrefs, and Google Scholar. 
 
Data synthesis 
As we anticipated insufficient methodological heterogeneity between study cohorts due to large 
variations in biomarker measurements and outcome measurements, calculating overall 
measures of effect was not considered appropriate. Consequently, a number of summary 
assessments were undertaken to critically appraise studies and collate the best available 
evidence. For biomarkers showing consistent effects across multiple studies, we reviewed 
proposed mechanisms and underlying hypotheses reported in manuscripts. We then developed 
a directed acyclic graph (DAG) using current evidence and scientific reasoning to examine the 
 
 8 
causal association between reported biomarkers and outcomes (Textor et al., 2016). We used 
the DAGitty R package and website (http://dagitty.net) to inspect the DAG and identify 





Search results and study characteristics 
Results of the literature search are shown in Figure 1, of 799 records we included 128 studies 
meeting our eligibility criteria for qualitative synthesis. Identified studies analysed different 
biomarkers either individually or using a composite measure of two related biomarkers (Table 
1). The majority of study populations were focused within mixed ICU admissions (n=74), 
followed by medical admissions (n=33) then surgical admissions (n=21) (online E2). Study 
designs were a combination of cohort studies (n=112) and case-control studies (n=16). All 
studies described a retrospective method of data collection. 
[Figure 1 near here] [Table 1 near here] 
 
Biomarker associations 
There was a total of 28 routinely measured parameters examined within identified studies, 20 
with one to four records, 3 with five to nine records, and 5 with ten or more records. Red cell 
distribution width (RDW) was the biomarker most frequently described (Table 1). Definitions 
of biomarker varied in terms of timing and frequency of measurements used. Single measures 
within 72 hours of admission were most common (68%) followed by 26% of studies using 
repeated measurements, and 6% of studies not clearly reporting when measures were taken. As 
studies used different biomarker cut offs, we were unable to compare size of associations 
between studies. Data reporting differed in using continuous variables (41.9%), categorical 
variables (46.0%), and 12.1% utilized increases between selected time-points. 
 
[Table 2 near here] 
For studies reporting the most frequently examined 5 biomarkers, relevant data extractions are 
summarized in Table 2 (remaining biomarkers are presented in online E1). Amongst defined 
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primary outcome variables, 10.5% of studies reported length of stay either on ICU and/or in 
hospital, the remaining 89.5% reported mortality. The majority of studies reported either death 
in ICU or in-hospital or mortality at 28 or 30-days. Seventeen studies reported mortality to 90 
days and two studies also reported longer term mortality to 1 and 5-years respectively. Patient 
inclusion criteria varied widely including sub-groups of patients admitted with intra-abdominal 
sepsis, sub-arachnoid haemorrhage, cardiac surgery, pneumonia, and renal failure. We were 
able to report overall trends for the most commonly investigated biomarkers. The biomarkers 
showing most consistently reported effects were RDW, platelet count, neutrophil-to-
lymphocyte ratio (NLR), and albumin. A higher RDW, a lower platelet count, and a higher 
NLR was associated with both mortality and increased ICU length of stay (Figure 2). A lower 
level of albumin was associated with mortality. All other reported biomarkers showed opposing 
directions of effect between different studies. 
[Figure 2 near here] 
 
Study impact 
Using maximum number of citations, 23.4% of studies were cited by ten or fewer other studies, 
20.2% of studies were cited by more than 50 other studies (Table 1). Within only the 128 
studies assessed in this review, 26 studies were cited by another study included in this review 
providing evidence of knowledge accumulation (online E5). However, of the top 5 cited papers, 
none were cited by a prospective study or randomized controlled trial.  
 
Study methodology 
All studies used a retrospective methodology and the chosen diagnostic test accuracy varied 
per study and target biomarker. Of studies reporting methods of statistical analysis, the majority 
(n=110) used logistic or linear regression, Cox proportional hazards survival modelling, or 
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both. Of 110 studies which adjusted for confounders, covariates were selected based on 
bivariate screening (n=41), stepwise selection (n=21), author based decision based on 
plausibility (n=26), Akaike information criterion (AIC) model fitting (n=1), and univariate p 
value threshold (n=1), the rest used unclear selection criteria (n=20).  
 
The most common method reported for model selection and performance was the Area under 
the ROC Curve (AUC) (n=61, 49.2%) and ranged from 0.57 to 0.91. Risk thresholds were not 
clearly reported. When multiple variables were included in a model, four studies reported 
criteria-based methods to guide model selection (2 used the log-likelihood and 2 used AIC). 
None of the studies reported pre-specified statistical analysis plans. None of the studies used 




In an exploratory approach we constructed a directed acyclic graph (DAG) for RDW and CRP, 
two of the most consistently reported biomarkers (Figure 3). For RDW, the DAG suggested 
three adjustment sets to test the direct effect of reactive erythropoeisis in response to the effects 
of prolonged critical illness. These comprised nutritional intake, cell hypoxia, and 
inflammation, which might be approximated using surrogate markers, respectively 
Malnutrition Universal Screening Tool (MUST) score, lactate, and CRP. Similarly, for CRP, 
an adjustment set to test the direct effect of prolonged inflammation on prolonged ICU stay 
included severity of illness and catabolism which could be approximated using admission 
SOFA/APACHE II scoring and urea-to-creatine ratio. Full code and methods for DAG 








Summary of results 
We performed a systematic review on routinely collected biomarkers and associations with 
prolonged length of stay and mortality following critical illness. Despite identifying a large 
number of independent studies constituting a significant amount of data, due to non-uniformity 
in variable definition, collection and reporting, interpretation was limited. Consequently, we 
were unable to increase the utility of these biomarkers by establishing consistent cut-offs in 
homogenous patient-groups. Strength of evidence for any reported biomarker remains low 
precluding the use of specific algorithms to guide clinical decision making, which remains 
based on heuristic interpretation of multiple data points by clinicians at the bedside. 
 
For the majority of reported biomarkers, the certainty of evidence for associations with 
outcomes was low or moderate, primarily due to imprecision in effect size and risk of bias. 
There was no evidence of pre-specification of statistical analyses, conversely there was 
evidence of selective reporting, two important standards suggesting low-quality evidence. 
There was limited use of longitudinal data despite the potential to greatly enrich predictions 
with appropriate analysis. Failure to consider longitudinal effects may account for reports of 
opposing directions of association for the same biomarker even within similar study 
populations.  
 
Some biologically plausible biomarkers have shown consistent effect in determining poor 
outcomes following critical illness. However, despite generating interest, citations and having 
coherent pathophysiological hypotheses, there has been little clinical uptake of decision models 
based on these parameters. All the studies we identified focused on determining statistical 
significance without evaluating underlying mechanisms or formally assessing utility of the 
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measured parameter in altering clinical practice. However, populations, cut-offs, outcomes 
measures, and adjustment for confounders varied considerably between studies. As a result, 
clear interpretation and meaningful application of these reported association remains lacking.  
 
Biological frameworks for prospective justification of variable selection 
In an exploratory analysis, we used a DAG methodology to explore RDW and CRP as 
examples of formalising variable selection for inclusion into a study model a priori, as an 
alternative more powerful technique to simple baseline characteristic adjustments in 
multivariable analysis. This method allows examination of proposed casual pathways. For 
example, a potential link between reactive erythropoiesis to low baseline levels and prolonged 
inflammation with prolonged duration of critical illness and increased mortality is pre-
specified. Visualisation of multiple variables which are likely to be inter-related allows 
investigators to pre-specify an adjustment set, reducing both inadequate correction for 
confounding and collider bias, both of which may mask real effects (Wunsch et al., 2006). This 
also gives an explicit statement of proposed mechanisms and avoids variable selection by bias-
prone methods (Lederer et al., 2019). Not all biomarkers follow the same trajectory and likely 
demonstrate different predictive value at different time points of disease. Improved 
understanding of underlying biological mechanisms will also strengthen the basis for setting 
biomarker thresholds and time of assessment thus improving the ability to detect true effects if 
present (Leisman et al., 2020). 
 
Strengths and limitations 
To our knowledge, this is the first systematic review evaluating routine blood tests as 
biomarkers within critical care populations. The strengths of this review include a 
comprehensive literature search, adherence to our pre-registered protocol, and focus on studies 
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which have specifically tested one or more biomarker(s) as their primary objective. However, 
we lacked sufficient data to explore subgroup effects, and significant study heterogeneity 
prevented formal meta-analysis and restricted further quantitative analysis of data. There may 
be some variation in which biomarkers are routinely measured between ICUs. Significant 
potential for publication bias exists, as evidenced by serial citation patterns and timescale of 
publications. Due to the breadth of our search terms, variations in the structure of study 
reporting, and exclusions of non-English articles, it is possible that some studies were missed.  
 
Recommendations 
In order to improve the quality and utility of future research, we propose three methodological 
recommendations for biomarker studies examining cohorts in critical illness. These are, to 
identify a prospective causal framework facilitating adequate selection of covariates and 
adjustment variables (Grimes and Schulz, 2002), use of a prospective analysis plan to reduce 
bias and multiple testing (Berger et al., 2012), and use of an external validation cohort to test 
accuracy and generalisability of proposed predictive models (Altman and Royston, 2000). 
Studies should also adhere to structured reporting guidelines such as STROBE or TRIPOD to 
improve comparability and transparency (von Elm et al., 2008, Collins et al., 2015). It should 
also be noted that many studies were carried out in similar populations, in particular a number 
used the freely accessible, single centre, MIMIC database. This highlights the need to increase 
diversity of study populations across different centres and countries to ensure generalizability. 
Where possible, patient level data sharing should be facilitated to increase power to assess 
association across multiple studies and allow validation of findings between studies. These 
principles are of key importance with increasing use of machine learning approaches, as 






Simple regression models with imprecise variable selection and adjustment have so far proved 
inadequate to derive consistent clinically applicable models from the complexity of routine 
blood test data. Previous research has had limited applicability, compounded by a lack of 
external validation. Machine learning approaches continue to face similar methodological 
challenges. Adoption of a direct causal framework may be needed a priori to better assess 
causal associations, increase biological understanding, and maximize learning from these 
studies. Improving current methodology in observational biomarker research in this field may 
help to identify candidates for use in predictive modelling and guide clinical decision making 
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Figure 1. PRISMA flowchart for the systematic review and meta-analysis. 
Figure 2. Summary of studies for biomarkers with 5 or more records. RDW: red cell 
distribution width, NLR: neutrophil-to-lymphocyte ratio, CRP: C-reactive protein, Na: sodium. 
Effect on outcomes defined as positive if increased and negative if decreased mortality or 
increased length of stay. See online supplement E7 for references and E8 for key to study 
names. 
Figure 3. Proposed directed acyclic graphs relating red cell distribution with (RDW) and C-
reactive protein (CRP) to mechanisms underlying prolonged critical illness. See online 
supplement E4 for full code and references to mechanistic pathways. 
